Response Biomedical Corporation Delivers Record Preliminary Revenues in Fir... (uture implementation and our expectation...)

Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter

Date:4/20/2009

uture implementation, and our expectations for our financial condition and the results of, or outlook for, our business operations generally. Forward-looking statements or information are subject to the related assumptions made by us and involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such statements or information.

Many of such risks, uncertainties and other factors form part of our underlying assumptions, and include, among other things, financial risks that would affect our operations such as our limited available working capital and cash flows and whether and for how long available funds will be sufficient to fund our operations and our ability to raise additional capital as and when needed; our need for substantial additional funding to conduct research and development and commercialization activities; current financial market conditions which may negatively affect our ability to obtain financing; our ability to meet the continued listing requirements of the TSX under its ongoing delisting review; changing facility costs and other risks relating to our facilities expansion plans; our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; technological changes that impact our existing products or our ability to develop and commercialize our products; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; our ability to obtain and maintain rights to technology from licensors; liability for patent, product liability and other claims asserted against us; commercialization limitations imposed by patents owned or controlled by third parties; technical risk in research and development; adverse results or unexpected delays in product development and clinical trials; our ability to retai
'/>"/>

SOURCE Response Biomedical Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Nationwide Foundation Donates $1.7 Million to American Red Cross for Disaster Preparedness and Response and Increased Blood Collections
2. Groundbreaking First Response Spray Now Available in Europe
3. Cigarette smoke may alter immune response in COPD exacerbations
4. Video: New First Response(R) Fertility Test Helps Women Answer the Question: Am I Able to Get Pregnant?
5. Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
6. Response to Association Between Hospital-Reported Leapfrog Safe Practices Scores and Inpatient Mortality, Journal of the American Medical Association (JAMA); April 1, 2009
7. Response Biomedical Corporation Reports 2008 Financial Results
8. Tray-Pak Direct Mailer Garners 21% Response, Design Award
9. 2-day results predict ultimate response to therapy in chronic hepatitis C
10. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
11. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition

Post Your Comments:

Response Biomedical Corporation Delivers Record Preliminary Revenues in Fir...(uture implementation and our expectation...),Health